Development
Sanofi
SNY
$48.22
-$1.19-2.41%
NASDAQ
| 12/31/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | 11.76B | 10.85B | 10.96B | 12.58B | |
| Total Other Revenue | 937.70M | 678.13M | 746.90M | 661.00M | |
| Total Revenue | 12.69B | 11.52B | 11.71B | 13.24B | |
| Cost of Revenue | 4.34B | 3.55B | 3.81B | 3.86B | |
| Gross Profit | 8.36B | 7.97B | 7.89B | 9.38B | |
| SG&A Expenses | 3.23B | 2.85B | 3.01B | 2.66B | |
| Depreciation & Amortization | 619.03M | 594.32M | 466.94M | 691.23M | |
| Other Operating Expenses | 1.61B | 1.07B | 860.32M | -414.13M | |
| Total Operating Expenses | 11.82B | 9.84B | 10.01B | 8.55B | |
| Operating Income | 877.41M | 1.68B | 1.70B | 4.69B | |
| Income Before Tax | -268.07M | 1.87B | 4.17B | 2.70B | |
| Income Tax Expenses | 332.66M | 294.98M | 929.80M | 605.58M | |
| Earnings from Continuing Operations | -600.73M | 1.58B | 3.24B | 2.09B | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | 3.23M | -13.06M | -58.24M | -3.02M | |
| Net Income | -597.50M | 1.56B | 3.18B | 2.09B | |
| EBIT | 877.41M | 1.68B | 1.70B | 4.69B | |
| EBITDA | 1.77B | 2.65B | 2.47B | 5.36B | |
| EPS Basic | -0.48 | 1.25 | 2.53 | 1.67 | |
| Normalized Basic EPS | 0.16 | 0.78 | 0.81 | -- | |
| EPS Diluted | -0.48 | 1.24 | 2.53 | 1.67 | |
| Normalized Diluted EPS | 0.16 | 0.78 | 0.81 | -- | |
| Average Basic Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | |
| Average Diluted Shares Outstanding | 1.25B | 1.25B | 1.25B | 1.25B | |
| Dividend Per Share | 4.05 | -- | 3.64 | -- | |
| Payout Ratio | -- | -- | -- | -- | |